As of November 6, 2026, Kezar Life Sciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 3, 2026 to May 11, 2026 (Form 8-K, May 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kezar Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kezar Life Sciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-03 to 2026-05-11. Every row below is cited to the filing it comes from, and this page adds each new change as Kezar Life Sciences, Inc. files it.
Layoffs on record: about 31 jobs, latest 2025-11-07 (layoff filings and notices).
Also on the record for Kezar Life Sciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 28, 2026 | Stake report, Schedule 13G/A, by Baselake Partners, LP | — | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Baselake Partners, LP | — | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | — | 5%+ stakes | Source |
| May 11, 2026 | Acquired by Aurinia Pharma U.S., Inc. | — | Acquisition | Source |
| April 6, 2026 | Stake report, Schedule 13G, by Baselake Partners, LP | 5.3% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | 9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Stonepine Capital Management, LLC | 2.1% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 9.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Avidity Partners Management LP | — | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kezar Life Sciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kezar Life Sciences, Inc. and the records around it.
Kezar Life Sciences, Inc. elsewhere on the record
- Acquisition May 2026
- Layoff notices Nov 2025
Companies that share a holder
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026)
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
Watch Kezar Life Sciences, Inc.
Get an email when Kezar Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kezar Life Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kezar Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kezar Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-11 | Reported | not named in the filing | 8-K, 2026-05-11 | ||
| 2026-04-03 | Reported | not named in the filing | 8-K, 2026-04-03 |
New leaders reset buying decisions — get the Full Report on Kezar Life Sciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Kezar Life Sciences, Inc., with the record behind each one.
Find candidates like senior executive at Kezar Life Sciences, Inc.Every change, in the filing's words
Reported
Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Pursuant to the terms of the Merger Agreement, at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
- Each officer's employment with the Company will terminate at the Effective Time.
- There were no disagreements between any of Mr. Kirk, Mr. Belsky and Mr. Schiller and the Company.
- Following the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, the sole director and officers of Merger Sub immediately prior to the Effective Time became the sole director and officers of the Surviving Corporation.
- The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.
- The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
Reported
Pursuant to the Separation Agreements, each Officer's employment with the Company will terminate at the Effective Time (as defined below).
- On April 1, 2026, the Company and each of Christopher J. Kirk, Ph.D., the Company's Chief Executive Officer, Marc L. Belsky, the Company's Chief Financial Officer and Secretary, and Mark Schiller, the Company's Chief Operating Officer (collectively, the "Officers"), entered into a Separation Agreement (collectively, the "Separation Agreements").
- Each Separation Agreement provides for severance benefits consistent with those resulting from a Covered Termination (as defined in each of Dr. Kirk's, Mr. Belsky's and Mr. Schiller's respective employment agreements) within three months prior to or twelve months following the effective date of a change in control under each of Dr. Kirk's, Mr. Belsky's and Mr. Schiller's respective employment agreements, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025.
- In addition, (i) Dr. Kirk will receive his Severance Payment (as defined in his respective Separation Agreement) in a lump sum, less applicable payroll deductions and withholdings, and (ii) each of Mr. Belsky and Mr. Schiller will be entitled to receive a one-time cash payment equal to 12 months of cost of health insurance premiums at the time of termination.
- The foregoing severance benefits are contingent upon a general release of claims set forth in the Separation Agreements.
Tools for this story
Each opens in a new tab, filled in for Kezar Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.